Fagron

Fagron
Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in 35 countries around the world.
Business Partner
Rafael Padilla
Website
www.fagron.be
Entry
2015
Point of contact
Els Degroote
Investment Principal

What do we do?

Pharmaceutical compounding involves the creation of non-patent protected or unregistered pharmaceutical preparations by or at the request of community or hospital pharmacies, based on a doctor’s prescription. Pharmaceutical compounding enables personalized treatment that is not standardly available, suited to a patient’s specific requirements.

As a vertically integrated global player, Fagron is active in the entire value chain of pharmaceutical compounding. Fagron is unique in offering a full range of products and services in pharmaceutical compounding to hospitals, pharmacies and clinics and it is unique in doing so globally.

"Fagron strives to make personalized medicine accessible to even more people. We do this together with pharmacists, doctors, hospitals, and the industry. By adjusting medication to a patient’s specific needs – personalizing medicine – treatments become less burdensome and accessible for more people."
Rafael Padilla, CEO – Fagron

Fagron’s dream

Fagron strives to create long-term value for all stakeholders: customers, patients, employees, investors, and society as a whole. “We increase the effectiveness of a treatment, the quality of life and patient safety. Ultimately, personalized medicine reduces healthcare costs. Fagron’s products and services contribute every day to improving the health of people worldwide.”

OTHER INVESTMENTS
Alychlo invests directly in companies, makes select fund investments and manages a long-term small- and mid-cap equities portfolio.